Literature DB >> 29266129

Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.

John M Findlay1,2, Kevin M Bradley3, Richard S Gillies1, Nicholas D Maynard1, Mark R Middleton4.   

Abstract

Entities:  

Year:  2017        PMID： 29266129      PMCID： PMC5723900          DOI： 10.21037/jtd.2017.09.54

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.

Authors:  John M Findlay; Kevin M Bradley; Lai Mun Wang; James M Franklin; Eugene J Teoh; Fergus V Gleeson; Nicholas D Maynard; Richard S Gillies; Mark R Middleton
Journal:  J Nucl Med       Date:  2016-09-15       Impact factor: 10.057

Review 2.  Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now.

Authors:  Tom P MacGregor; Tim S Maughan; Ricky A Sharma
Journal:  J Clin Pathol       Date:  2012-06-25       Impact factor: 3.411

Review 3.  Current-day precision oncology: from cancer prevention, screening, drug development, and treatment - have we fallen short of the promise?

Authors:  Gilberto Morgan; Philippe Aftimos; Ahmad Awada
Journal:  Curr Opin Oncol       Date:  2016-09       Impact factor: 3.645

4.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

5.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

6.  Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.

Authors:  J M Findlay; K M Bradley; L M Wang; J M Franklin; E J Teoh; F V Gleeson; N D Maynard; R S Gillies; M R Middleton
Journal:  Br J Surg       Date:  2017-01-17       Impact factor: 6.939

Review 7.  A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.

Authors:  J M Findlay; M R Middleton; I Tomlinson
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

8.  Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.

Authors:  John M Findlay; Francesc Castro-Giner; Seiko Makino; Emily Rayner; Christiana Kartsonaki; William Cross; Michal Kovac; Danny Ulahannan; Claire Palles; Richard S Gillies; Thomas P MacGregor; David Church; Nicholas D Maynard; Francesca Buffa; Jean-Baptiste Cazier; Trevor A Graham; Lai-Mun Wang; Ricky A Sharma; Mark Middleton; Ian Tomlinson
Journal:  Nat Commun       Date:  2016-04-05       Impact factor: 14.919
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.